{
  "id": 1677146,
  "title": "Citizens reiterates Docusign stock rating on federal business strength",
  "url": "https://urgent.news/2026/08/18/citizens-reiterates-docusign-stock-rating-on-federal-business-strength",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T09:02:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/citizens-reiterates-docusign-stock-rating-on-federal-business-strength-93CH-4864528"
  },
  "original_language": "en",
  "account": null,
  "summary": "Citizens analyst Patrick Walravens has maintained a Market Outperform rating and a $86.00 price target for Docusign Inc. (NASDAQ:DOCU). This target is in line with the firm's Fair Value estimate of $83.28, indicating the stock may be undervalued at its current price of $59.82. The analyst highlighted Docusign's strong federal business, which secured two awards exceeding $1 million in the second fiscal quarter of fiscal year 2027, including a $3.3 million award from the Department of Homeland Security and a $2.3 million award from the General Services Administration. The company's impressive gross profit margins of nearly 80% and revenue of $3.29 billion over the last twelve months further support the rating.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Citizens reiterates TuHURA Biosciences stock rating on pipeline progress",
        "url": "https://urgent.news/2026/08/18/citizens-reiterates-tuhura-biosciences-stock-rating-on-pipeline",
        "published": "2026-08-18T09:02:51.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}